Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Antepowicz, Agata, Habib, Omar, Kirsebom, Freja, Johansson, Cecilia, Gill, Deborah R., Hyde, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333317/
https://www.ncbi.nlm.nih.gov/pubmed/34344952
http://dx.doi.org/10.1038/s41598-021-95150-z
_version_ 1783732999553024000
author Antepowicz, Agata
Habib, Omar
Kirsebom, Freja
Johansson, Cecilia
Gill, Deborah R.
Hyde, Stephen C.
author_facet Antepowicz, Agata
Habib, Omar
Kirsebom, Freja
Johansson, Cecilia
Gill, Deborah R.
Hyde, Stephen C.
author_sort Antepowicz, Agata
collection PubMed
description Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
format Online
Article
Text
id pubmed-8333317
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83333172021-08-05 Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection Antepowicz, Agata Habib, Omar Kirsebom, Freja Johansson, Cecilia Gill, Deborah R. Hyde, Stephen C. Sci Rep Article Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations. Nature Publishing Group UK 2021-08-03 /pmc/articles/PMC8333317/ /pubmed/34344952 http://dx.doi.org/10.1038/s41598-021-95150-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Antepowicz, Agata
Habib, Omar
Kirsebom, Freja
Johansson, Cecilia
Gill, Deborah R.
Hyde, Stephen C.
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_full Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_fullStr Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_full_unstemmed Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_short Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
title_sort lentiviral and aav-mediated expression of palivizumab offer protection against respiratory syncytial virus infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333317/
https://www.ncbi.nlm.nih.gov/pubmed/34344952
http://dx.doi.org/10.1038/s41598-021-95150-z
work_keys_str_mv AT antepowiczagata lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
AT habibomar lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
AT kirsebomfreja lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
AT johanssoncecilia lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
AT gilldeborahr lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection
AT hydestephenc lentiviralandaavmediatedexpressionofpalivizumabofferprotectionagainstrespiratorysyncytialvirusinfection

Ejemplares similares